Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (3098)	12/3/1997 11:44:00 PM
From: WMG	Read Replies (4) of 6136

Good synopsis Margie. Having spent three years as Business Development Director with a private BioPharm company and having spent many days in talks and negotiations with Agouron, I can personally tell you that Agouron is one of the best managed BioPharms in the industry. Pulling the plug on a marginal compound like Thymataq is smart business sense. Their MMP inhibitor has a lot more promise, even if it is somewhat difficult to synthesize. But, I have no doubt that a more efficient route of synthesis will be developed. Don't forget that British Biotech has two MMP inhibitors in variuos phases of clinical trials and has a market cap of over $500MM, with no drug on the market. To the critics who profess that AGPH is now "just a one drug company", every BioTech company was a "one drug company" in their infancy. Agouron has an impressive pipeline, not to broad and diffusive to be unfocused, and not to narrow so as to bet the companies future on the prospects of one particular technology. Amgen had severe downdrafts of 30-50% while it was on its way from $1 to $100 (adjusted for splits). AGPH stock is CHEAP at today's price. Today's price is an opportunity... do you hear it knocking? WMG

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next